Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines.

Autor: Yamout B; Neurology Institute and Multiple Sclerosis Center, Harley Street Medical Center, Abu Dhabi, United Arab Emirates. Electronic address: yamoutba@gmail.com., Al-Jumah M; InterHealth hospital, Multiple Sclerosis Center, Riyadh, Saudi Arabia., Sahraian MA; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran., Almalik Y; Division of Neurology, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, Saudi Arabia., Khaburi JA; Department of Neurology, The Royal Hospital, Sultanate of Oman., Shalaby N; Neurology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt., Aljarallah S; King Saud University, Saudi Arabia., Bohlega S; King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia., Dahdaleh M; Al Khalidi Hospital, Amman, Jordan., Almahdawi A; Consultant Neurologist, Neurology Unit, Baghdad Teaching Hospital, Medical City Complex, Iraq., Khoury SJ; Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon., Koussa S; Multiple Sclerosis Center, Geitaoui Lebanese University Hospital, Beirut, Lebanon., Slassi E; Hôpital Cheikh Khalifa Ibn Zaid, Casablanca, Morocco., Daoudi S; Hospital Center Nedir Mohamed, Faculty of Medicine, University Mouloud Mammeri Tizi-Ouzou, Algeria., Aref H; Neurology Department, Ain Shams University, Cairo, Egypt., Mrabet S; Department of Neurology, CIC, Razi Universitary Hospital, University of Tunis El Manar, Tunis, Tunisia., Zeineddine M; Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS), Beirut, Lebanon., Zakaria M; Ain Shams University, Cairo, Egypt., Inshasi J; Department of Neurology, Rashid Hospital and Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates., Gouider R; Department of Neurology, CIC, Razi Universitary Hospital, University of Tunis El Manar, Tunis, Tunisia., Alroughani R; Amiri Hospital, Arabian Gulf Street, Sharq, Kuwait.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2024 Mar; Vol. 83, pp. 105435. Date of Electronic Publication: 2024 Jan 07.
DOI: 10.1016/j.msard.2024.105435
Abstrakt: With evolving diagnostic criteria and the advent of new oral and parenteral therapies for Multiple Sclerosis (MS), most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination in space and time and exclude alternative diseases that can explain the findings at hand. The differential diagnostic workup should be guided by clinical and laboratory red flags to avoid unnecessary tests. Appropriate selection of MS therapies is critical to maximize patient benefit. The current guidelines review the current diagnostic criteria for MS and the scientific evidence supporting treatment of acute relapses, radiologically isolated syndrome, clinically isolated syndrome, relapsing remitting MS, progressive MS, pediatric cases and pregnant women. The purpose of these guidelines is to provide practical recommendations and algorithms for the diagnosis and treatment of MS based on current scientific evidence and clinical experience.
Competing Interests: Declaration of competing interest The authors received honoraria from Biologix (the distributor for Biogen Idec across the Middle East and North Africa region) for serving on their advisory board and from other pharmaceutical companies including Novartis, GSK, Bayer, Merck, Sanofi and Roche. The manuscript represents the views and opinions of the members involved in the development of the guidelines. There is no industrial or pharmaceutical support or bias in the selection of the members or the recommendations reached. This effort was sponsored and carried out under the supervision of MENACTRIMS (The Middle East and North Africa Committee for Treatment and Research In Multiple Sclerosis).
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: